JP2017523805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523805A5 JP2017523805A5 JP2017523183A JP2017523183A JP2017523805A5 JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5 JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lcdr
- hcdr
- antibody
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 241000713196 Influenza B virus Species 0.000 claims description 26
- 101710154606 Hemagglutinin Proteins 0.000 claims description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 18
- 101710176177 Protein A56 Proteins 0.000 claims description 18
- 239000000185 hemagglutinin Substances 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 208000037798 influenza B Diseases 0.000 claims description 14
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 208000037797 influenza A Diseases 0.000 claims description 8
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 claims description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 claims 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024804P | 2014-07-15 | 2014-07-15 | |
| US62/024,804 | 2014-07-15 | ||
| PCT/US2015/040385 WO2016011035A2 (en) | 2014-07-15 | 2015-07-14 | Neutralizing anti-influenza b antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Division JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523805A JP2017523805A (ja) | 2017-08-24 |
| JP2017523805A5 true JP2017523805A5 (enExample) | 2018-08-23 |
| JP6837434B2 JP6837434B2 (ja) | 2021-03-03 |
Family
ID=55079157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523183A Active JP6837434B2 (ja) | 2014-07-15 | 2015-07-14 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10294292B2 (enExample) |
| EP (1) | EP3169407A4 (enExample) |
| JP (4) | JP6837434B2 (enExample) |
| CN (4) | CN106573154B (enExample) |
| AU (3) | AU2015289805B2 (enExample) |
| BR (1) | BR112017000640A2 (enExample) |
| CA (1) | CA2954780A1 (enExample) |
| MX (3) | MX392761B (enExample) |
| RU (2) | RU2711932C2 (enExample) |
| WO (1) | WO2016011035A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| CN106573154B (zh) | 2014-07-15 | 2021-06-15 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| BR112017025496A2 (pt) * | 2015-06-01 | 2018-08-07 | Medimmune, Llc | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas |
| US20190015509A1 (en) | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
| EP4051707A1 (en) * | 2019-10-28 | 2022-09-07 | Regeneron Pharmaceuticals, Inc. | Anti-hemagglutinin antibodies and methods of use thereof |
| CN112048006B (zh) * | 2020-09-08 | 2021-04-27 | 扬州大学 | 一种替代中和效力测定的elisa方法及其应用 |
| WO2023102398A2 (en) * | 2021-11-30 | 2023-06-08 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof |
| CN118420751B (zh) * | 2022-07-09 | 2025-04-08 | 东莞市朋志生物科技有限公司 | 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6071251A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| JP4528989B2 (ja) * | 1999-03-31 | 2010-08-25 | 学校法人慶應義塾 | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
| JP4656478B2 (ja) | 2000-02-22 | 2011-03-23 | 株式会社医学生物学研究所 | 抗体ライブラリー |
| ATE309385T1 (de) | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| EP1551875A4 (en) | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| US7175999B2 (en) | 2002-07-11 | 2007-02-13 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| CN1934133B (zh) | 2003-07-23 | 2011-12-14 | 富士瑞必欧株式会社 | 抗a型流感病毒单克隆抗体及使用该抗体的免疫测定器具 |
| EP1666059A4 (en) | 2003-08-11 | 2008-08-27 | Univ Osaka Res Found | NEW VACCINE WITH AN ADJUVANS FOR TRIGGERING ABSORBENT IMMUNITY |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| US8716557B2 (en) | 2006-01-17 | 2014-05-06 | Synthon Biopharmaceuticals B.V. | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants |
| CA2647380A1 (en) | 2006-03-21 | 2007-09-27 | David T. Weaver | Methods for humanizing antibodies and humanized antibodies made thereby |
| US7615220B2 (en) | 2006-04-07 | 2009-11-10 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-18 receptor |
| US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
| US8192927B2 (en) | 2006-09-07 | 2012-06-05 | Crucell Holland B.V. | Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| MX2009003393A (es) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | Anticuerpos humanos de alta afinidad para el receptor de il-4 humano. |
| WO2008066691A2 (en) | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7 and antibodies that bind thereto |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| WO2008110937A2 (en) | 2007-03-13 | 2008-09-18 | Humabs Llc | Antibodies against h5n1 strains of influenza a virus |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| AU2009275226B2 (en) | 2008-07-25 | 2015-05-14 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP4071169A2 (en) | 2008-08-25 | 2022-10-12 | Dana Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| US9534042B2 (en) * | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| EP2652496B1 (en) | 2010-12-13 | 2018-01-17 | The University of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| CN103906763B (zh) * | 2011-07-14 | 2016-10-12 | 克鲁塞尔荷兰公司 | 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子 |
| SI2734545T1 (sl) | 2011-07-18 | 2019-06-28 | Institute For Research In Biomedicine | Protitelesa, ki nevtralizirajo virus influence A in njihova uporaba |
| US10131695B2 (en) | 2011-09-20 | 2018-11-20 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| WO2013086052A2 (en) * | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| WO2013132007A1 (en) * | 2012-03-08 | 2013-09-12 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| EA201892509A1 (ru) | 2012-11-13 | 2019-04-30 | Дженентек, Инк. | Антитела к гемагглютинину и способы применения |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| RU2536956C1 (ru) | 2013-08-05 | 2014-12-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" | Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а |
| ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| CN106573154B (zh) * | 2014-07-15 | 2021-06-15 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| BR112017025496A2 (pt) | 2015-06-01 | 2018-08-07 | Medimmune, Llc | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas |
| US20190015509A1 (en) | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
| JP7104629B2 (ja) | 2016-02-24 | 2022-07-21 | ビステラ， インコーポレイテッド | インフルエンザウイルスに対する抗体分子の製剤 |
-
2015
- 2015-07-14 CN CN201580038244.1A patent/CN106573154B/zh active Active
- 2015-07-14 WO PCT/US2015/040385 patent/WO2016011035A2/en not_active Ceased
- 2015-07-14 AU AU2015289805A patent/AU2015289805B2/en active Active
- 2015-07-14 EP EP15821645.7A patent/EP3169407A4/en active Pending
- 2015-07-14 CN CN202110634430.9A patent/CN113173990B/zh active Active
- 2015-07-14 CA CA2954780A patent/CA2954780A1/en active Pending
- 2015-07-14 JP JP2017523183A patent/JP6837434B2/ja active Active
- 2015-07-14 MX MX2017000595A patent/MX392761B/es unknown
- 2015-07-14 CN CN202410982380.7A patent/CN119161468A/zh active Pending
- 2015-07-14 RU RU2017104638A patent/RU2711932C2/ru active
- 2015-07-14 BR BR112017000640A patent/BR112017000640A2/pt not_active Application Discontinuation
- 2015-07-14 RU RU2020100073A patent/RU2739952C2/ru active
- 2015-07-14 US US15/325,603 patent/US10294292B2/en active Active
- 2015-07-14 CN CN202110634379.1A patent/CN113563462B/zh active Active
-
2017
- 2017-01-13 MX MX2022006561A patent/MX2022006561A/es unknown
- 2017-01-13 MX MX2022006558A patent/MX2022006558A/es unknown
-
2019
- 2019-03-22 US US16/361,653 patent/US10519221B2/en active Active
- 2019-11-07 US US16/676,974 patent/US11174304B2/en active Active
-
2020
- 2020-09-15 AU AU2020233635A patent/AU2020233635B2/en active Active
-
2021
- 2021-02-09 JP JP2021018692A patent/JP7209754B2/ja active Active
- 2021-10-12 US US17/499,495 patent/US11787853B2/en active Active
-
2023
- 2023-01-10 JP JP2023001445A patent/JP7453430B2/ja active Active
- 2023-09-08 US US18/463,736 patent/US12325740B2/en active Active
-
2024
- 2024-03-07 JP JP2024034654A patent/JP2024069341A/ja active Pending
- 2024-04-08 AU AU2024202231A patent/AU2024202231A1/en active Pending
-
2025
- 2025-05-08 US US19/202,812 patent/US20250263470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240425617A1 (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
| JP2017523805A5 (enExample) | ||
| US11926657B2 (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| JP2016538876A5 (enExample) | ||
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
| JP6371222B2 (ja) | インフルエンザの受動免疫用抗体 | |
| CN115515976A (zh) | 冠状病毒抗体 | |
| JP2018514193A5 (enExample) | ||
| CN105358575B (zh) | 干扰素α和ω抗体拮抗剂 | |
| WO2018213097A1 (en) | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof | |
| HK40061503B (zh) | 中和抗流感结合分子及其用途 | |
| HK40061503A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| HK40069730A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| WO2024108088A1 (en) | Lag-3 and pd-1/lag-3-antibodies | |
| HK40040395B (zh) | 用於治疗癌症的组合物和方法 | |
| HK1250725B (zh) | 中和抗流感结合分子及其用途 | |
| HK1253092B (en) | Neutralizing anti-influenza binding molecules and uses thereof |